Sign inTry free

GH Research (GHRS) stock

Mebufotenin for depression , market cap $1.4B

$21.11
+3.23%

Market closed. Prices as of today's close.

Quality Score
4
Below Average
In its industry
#32of 94
Pharma

Holding it back: 10.7% more shares than a year ago, from Massive's market data. 3 more reasons behind GHRS's 4, for Pro members.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

See all 14 checks on GHRSSee it live, free until Tuesday morning. No account. No card. Then keep going with a free account.

What's next

Expected to report Thu Nov 5, before the open

After its last 3 reports it closed -1.6% on average, higher 1 of 3 times.

For Pro members

  • What would turn GHRS's score around: 6 things

Why GHRS scores 4

Below AverageTrending up, 4 of 14 checks firingWhat the Quality Score means

Poor is below 0. Average starts at 6, Above Average at 11, Excellent at 15, and Exceptional at 20.

  • +4Chart checks 4 of 14 firing right now, one point each
  • +1Long-term trend below a rising 200-⁠day average
  • Run-up adds
  • Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
  • Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.

No effect today: Size, Profit, Growth, Cash flow, Persistence, and News.

What every line is worth, and the reason behind it, on GHRS and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 9:27 PM ET, at least 15 minutes behind. How we rank stocks.

Alert me when GHRS's Quality Score turns up

See it live, free until Tuesday morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

  • The same page for Pro members, on AMD

    Its Quality Score and rank, the line that drives it, and the live price with the bid and ask.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on GHRS and every other stock.

  • Why a stock ranks

    Its Quality Score, its rank, and the reasons behind it, on one card.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, download a CSV, and set optional alerts.

  • Congress trades

    Each member's trades. Sort, filter, download a CSV, and set optional alerts.

  • All 14 chart checks

    Trend, volume, tight range, and buying, each lit when it fires, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports. Optional alerts before them.

  • FDA dates, counted down

    Each date in the company's own words, its cash against the date, and an optional alert before it.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    AI chips, quantum, nuclear, defense, space, and more, each stock ranked by its Quality Score.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push, email, or the bell.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name, with optional alerts.

  • A trade plan, from the chart

    Entry, stop, and two targets on every stock's page. Type your risk and it sizes the trade.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

GHRS has 4 of 14 checks firing

One per group is shown here.

Trend1 of 5 shown
MA FAN21 EMAW.EMAHH/HL52W HI

Averages stacked in order, price near its high.

Volume1 of 3 shown
VOLVDUU/D VOL

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown
ATR SQZSQUEEZENR7

The daily range is tight against its own recent history.

Buying1 of 3 shown
OBV+CLOSE HISPRING

Closes near the high, and buyers step in on dips.

The other 10 checks on GHRS, and all 14 on every stock.Get in free →

Also on the chart

Not scored

Shown for reference. None of these counts toward the Quality Score: in our tests on 20 years of daily prices, none of them improved it.

  • RSI 1429.0

    Below 30.

  • MACD (12, 26, 9)Below signal

    Crossed below its signal line 12 sessions ago.

  • 50-day average$27.07

    The price is 22.0% below it.

  • 200-day average$21.18

    The price is 0.3% below it. The 50-day is above the 200-day, since Feb 25, 2025.

  • ADX 1431.7

    25 or more, with +DI below -DI.

  • Support$20.00

    Swing low from May 14, 5.3% below the price.

  • Resistance$22.88

    Swing high from May 6, 8.4% above the price.

  • Bollinger Bands (20, 2)Inside

    The bands run from $19.23 to $30.16.

  • Volume0.5x

    Against its 20-day average, for the time of day.

How GHRS ranks in Pharma

GHRS is #32 of 94 by Quality Score. The top three are shown with their scores, and more by name.

More in Pharma, on the Healthcare page

When does GHRS report earnings, and what happens after?

Expected to report Thu Nov 5, before the open (in 27 days). Not yet confirmed by the company.

ReportedGapReaction5 sessions
May 14, 2026Before open-1.7%+1.5%+3.0%
Mar 5, 2026Before open-0.3%-5.1%-5.4%
Nov 6, 2025Before open-1.3%-1.3%+10.4%

The gap is the next open against the close before the report; the reaction is where that session closed. GHRS closed higher after 1 of its last 3. Past behavior, not a forecast.

Report dates and past reactions come from sessions that have already closed, so none of these figures move.

About GH Research

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

73 employeesghres.com

Pro members see every line of every stock's score.

  • Real-⁠time prices, no delay
  • Every line of GHRS's score, with the points and the reason
  • All 14 checks on GHRS and on all 3,277 stocks
  • Every stock ranked, with the chart
  • Every filing, and optional alerts on GHRS
See all 14 checks on GHRSSee it live, free until Tuesday morning. No account. No card. Then keep going with a free account.

Straight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders, and profits come straight from the SEC. That means Form 4 filings, 13F filings, and XBRL financial data on EDGAR. Where a company's SEC figures leave the Quality Score's sales, share count, or cash flow line empty, the score reads that figure from Massive's statements, and the Score tab says so. A foreign company that files its quarters on Form 6-K has them read from those filings' own statements, every figure as the filing prints it. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch, and Yahoo Finance publish, shown as the headline, the source, and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.